Results 81 to 90 of about 8,055 (251)

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

Andrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul, Michal Dubský, Aneta Hujová, Michaela Liegertová   +3 more
wiley   +1 more source

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model

Frontiers in Endocrinology
IntroductionParkinson’s disease (PD) is a progressive neurodegenerative disorder for which there is no cure. Diabetes is one of the risk factors for developing PD.
Zhang Lingyu, Feng Peng, Zhong Wanting, Jin Qianqian, Zijuan Zhang, Bo Bai, Guofang Xue, Christian Hölscher   +7 more
doaj   +1 more source

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes [PDF]

Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight.
D'Alessio David, Nauck Michael A, Herschtal Alan, Menon Venu, Nissen Steven E, Sattar Naveed, Zinman Bernard, Nishiyama Hiroshi, Basile Jan, McGuire Darren K, Weerakkody Govinda, Nicholls Stephen J, Wiese Russell J, Giorgino Francesco, Bhatt Deepak L, Várkonyi Tamás, Miller Debra, Kollaborációs szervezet: SURPASS-CVOT Investigators, Davies Melanie J, Lincoff A Michael, Kellerer Monika, Broder Jonathan C, Pavo Imre, Ji Linong, Kahn Steven E, Zoungas Sophia, Buse John B, et al., Del Prato Stefano   +28 more
core   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A

Genes and Diseases
Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by excessive hepatic lipid accumulation. This study evaluated the therapeutic effects and molecular mechanisms of tirzepatide, a dual GIP and GLP-1 receptor agonist, in treating ...
Yun Li, Wencong Sun, Hong Liu, Xiong Z. Ruan   +3 more
doaj   +1 more source

Tirzepatide and exercise training in obesity

Objectives: The purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and ...
Marzetti, Emanuele
core   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol

Obesity Pillars
Introduction: Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant ...
Jessica Duncan, Patrick Lee Stevens, Emily Bigby, Courtney Floyd, Josh Malina, Jennifer Nickens, Amber Lambert, Taylor Kantor   +7 more
doaj   +1 more source